Zevra Therapeutics Amends Bylaws, Changes Fiscal Year

TL;DR

**Zevra Therapeutics just updated its corporate rules and fiscal year, signaling potential internal restructuring or strategic changes.**

AI Summary

Zevra Therapeutics, Inc. filed an 8-K on February 28, 2024, reporting an event that occurred on February 22, 2024. The filing indicates amendments to its Articles of Incorporation or Bylaws and changes in its fiscal year. The company, incorporated in Delaware with IRS Employer Identification No. 20-5894398, is headquartered at 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747.

Why It Matters

Changes to a company's foundational documents like Articles of Incorporation or Bylaws can impact corporate governance, shareholder rights, and operational flexibility, potentially signaling strategic shifts or compliance updates.

Risk Assessment

Risk Level: low — This filing primarily reports administrative changes to corporate documents and fiscal year, which are generally low-risk events unless specific details reveal adverse impacts.

Key Players & Entities

• Zevra Therapeutics, Inc. (company) — Registrant
• Delaware (company) — State of incorporation
• 20-5894398 (dollar_amount) — IRS Employer Identification No.
• February 22, 2024 (date) — Date of earliest event reported
• February 28, 2024 (date) — Filed as of date

FAQ

Key Financial Figures

• $0.0001 — e on which registered Common Stock , $0.0001 par value per share ZVRA The Nasdaq

Filing Documents

• zvra20240228_8k.htm (8-K) — 35KB
• ex_632349.htm (EX-3.1) — 131KB
• 0001437749-24-005904.txt ( ) — 330KB
• zvra-20240222.xsd (EX-101.SCH) — 3KB
• zvra-20240222_def.xml (EX-101.DEF) — 12KB
• zvra-20240222_lab.xml (EX-101.LAB) — 15KB
• zvra-20240222_pre.xml (EX-101.PRE) — 12KB
• zvra20240228_8k_htm.xml (XML) — 3KB

03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On February 22, 2024, the board of directors (the "Board") of Zevra Therapeutics, Inc. (the "Company") approved and adopted the Company's amended and restated bylaws (the "Amended and Restated Bylaws") which became effective the same day. Among other things, the amendments contained in the Amended and Restated Bylaws: address the universal proxy rules adopted by the U.S. Securities and Exchange Commission, by providing that no person may solicit proxies in support of a director nominee other than the Board's nominees unless such person has, or is part of a group that has, complied with Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including applicable notice and solicitation requirements; update disclosure requirements in connection with stockholder nominations of directors and submissions of proposals regarding other business at stockholder meetings (other than proposals to be included in the Company's proxy materials pursuant to Rule 14a-8 under the Exchange Act); and require that a stockholder directly or indirectly soliciting proxies from other stockholders use a proxy card color other than white. The Amended and Restated Bylaws also incorporate certain technical, modernizing, clarifying and conforming changes, including to reflect updates in the Delaware General Corporation Law. Pursuant to Delaware law, the Company's amended and restated certificate of incorporation, and the Company's amended and restated bylaws prior to the amendments, a stockholder vote was not necessary to effectuate these changes. The foregoing description of the Amended and Restated Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended and Restated Bylaws, a copy of which is filed as Exhibit 3.1 with this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Amended and Restated Bylaws of Zevra Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Zevra Therapeutics, Inc . Date: February 28, 2024 By: /s/ Timothy J. Sangiovanni Timothy J. Sangiovanni, CPA Senior Vice President, Corporate Controller

View Full Filing

View this 8-K filing on SEC EDGAR